On The Horizon- Coming Soon – Radium-223 (Alpharadin) A Bone Targeted Treatment for Advanced Prostate Cancer that Extends Life

At the recent European Multidisciplinary Cancer Congress in Stockholm, Dr Chris Parker from The Royal Marsden Hospital presented results of the phase 3 ALSYMPCA trial that showed both delayed time to first skeletal-related event (SRE) AND an overall survival (OS) benefit for those men with advanced prostate cancer taking radium-223 (Alpharadin). The real significance of [...]

Should Bisphosphonates Use Be Limited- An FDA Panel Waffles on Limiting Duration

A recent meeting of an FDA advisory committee has asked wants the FDA to limit the duration of bisphosphonate therapy for treatment of osteoporosis, but the committee could not agree on a time limit to recommend. […]

A Video on Bone Metastases & Zometa

I recently made a video with Dr. James Mckiernan of Columbia Presbyterian Hospital in New York City on the use of Zometa (zoledronic acid) to combat bone metastases in advanced prostate cancer that is castrate resistant. Novartis Oncology, the makers of Zometa, sponsored the video and it was produced on the Wego Health web page. [...]

Should Men on ADT Take Calcium and Vitamin D Supplementation?

As usual with prostate cancer there is no general agreement about whether or not men who are on a hormone blockade (ADT) to treat prostate cancer should be taking calcium and vitamin D supplements, however there does seem to be some consensus that they should. Given that there are geographic and seasonal variations in vitamin [...]

Timely Use of Zoledronic Acid Provides Both Longer Hospital Free Survival and Increased Survival

A recent study conducted at the Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA by the Section of Hematology and Medical Oncology, Tulane University School of Medicine, New Orleans, LA, evaluated the efficacy of the timely use of zoledronic acid (ZA) on clinical outcomes and health care utilization in men with bone-metastatic prostate [...]

Go to Top